LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 13, Issue 608, Pages eabf5107
Publisher
American Association for the Advancement of Science (AAAS)
Online
2021-08-26
DOI
10.1126/scitranslmed.abf5107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma
- (2020) Benjamin P. Fairfax et al. NATURE MEDICINE
- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- (2020) Hirofumi Ohmura et al. BRITISH JOURNAL OF CANCER
- FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
- (2020) Matthew Kraman et al. CLINICAL CANCER RESEARCH
- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
- (2020) Mariaelena Capone et al. Journal of Translational Medicine
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- (2020) Kobe C. Yuen et al. NATURE MEDICINE
- MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
- (2020) Jiae Koh et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
- (2020) Je-In Youn et al. Scientific Reports
- Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
- (2020) Lawrence P. Andrews et al. Science Immunology
- Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering
- (2020) Arshi Arora et al. Genome Medicine
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
- (2019) Diego Signorelli et al. Biomed Research International
- Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab
- (2019) Michael A. Postow et al. MELANOMA RESEARCH
- Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
- (2019) Jonas Bochem et al. PLoS One
- Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
- (2019) Lawrence P. Andrews et al. NATURE IMMUNOLOGY
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
- (2019) Hiroshi Kagamu et al. Cancer Immunology Research
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.
- (2018) Melissa A. Eastgate et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-conventional Inhibitory CD4+Foxp3–PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- (2018) Roberta Zappasodi et al. CANCER CELL
- Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients
- (2017) Kilian Wistuba-Hamprecht et al. EUROPEAN JOURNAL OF CANCER
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
- (2017) Jeffrey S. Weber et al. Cancer Immunology Research
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started